These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3234732)

  • 1. [Kinetic characteristics of tumor growth in multiple myeloma].
    Golenkov AK; Kasatkina VV; Kozinets GI; Zlatkina AR
    Gematol Transfuziol; 1988 Dec; 33(12):34-6. PubMed ID: 3234732
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
    Marchica V; Accardi F; Storti P; Mancini C; Martella E; Dalla Palma B; Bolzoni M; Todoerti K; Marcatti M; Schifano C; Bonomini S; Sammarelli G; Neri A; Ponzoni M; Aversa F; Giuliani N
    Int J Hematol; 2017 Jan; 105(1):104-108. PubMed ID: 27699576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.
    Saburi M; Ogata M; Soga Y; Kondo Y; Kurimoto R; Itani K; Kohno K; Uchida H; Nakayama T
    J Clin Exp Hematop; 2020; 60(1):17-20. PubMed ID: 32224561
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
    Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
    Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission.
    Galani Z; Viniou N; Kyrtsonis MC; Sachanas S; Antoniou T; Dimopoulou MN; Vassilakopoulos TP; Korkolopoulou P; Nakopoulou L; Patsouris E; Pangalis GA
    Anticancer Res; 2007; 27(1B):571-4. PubMed ID: 17348443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow plasma cell infiltration in multiple myeloma.
    de Gramont A; Benitez O; Smadja N; Brissaud P; Sirinelli A; Hubert D; Krulik M; Debray J
    Br J Haematol; 1984 Jun; 57(2):351-3. PubMed ID: 6733051
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple Myeloma With Multilobated Plasma Cells: An Unusual and Challenging Morphological Variant.
    Zanelli M; Mengoli MC; Fanni D; Froio E; De Marco L; Ascani S
    Int J Surg Pathol; 2018 Aug; 26(5):439. PubMed ID: 29279032
    [No Abstract]   [Full Text] [Related]  

  • 8. [Multiple myeloma].
    Hsu DC; Wilkenfeld P; Joshua DE
    Praxis (Bern 1994); 2012 Jun; 101(13):857-61. PubMed ID: 22715077
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in the diagnosis and management of myeloma.
    Greipp PR
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):24-45. PubMed ID: 1509293
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasmablastic multiple myeloma with Dutcher bodies.
    Jain D; Singh T
    Indian J Pathol Microbiol; 2008; 51(3):442-3. PubMed ID: 18723987
    [No Abstract]   [Full Text] [Related]  

  • 11. Initial bone marrow findings in multiple myeloma. Significance of plasma cell nodules.
    Buss DH; Prichard RW; Hartz JW; Cooper MR; Feigin GA
    Arch Pathol Lab Med; 1986 Jan; 110(1):30-3. PubMed ID: 3753566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cell myeloma marrow diagnosis including morphologic and phenotypic features.
    Grogan TM
    Semin Diagn Pathol; 2003 Aug; 20(3):211-25. PubMed ID: 14552432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.
    Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S
    Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical importance of studying the proliferative activity of plasma cells in multiple myeloma].
    Tsykalov VA; Kasatkina VV; Kotel'nikov VM; Zhuravlev VS; Mokeeva RA
    Gematol Transfuziol; 1988 Jul; 33(7):36-40. PubMed ID: 3181725
    [No Abstract]   [Full Text] [Related]  

  • 15. [Plasma cell separation algorithm from bone marrow samples].
    Buresová I; Kyjovská D; Kovárová L; Moravcová J; Suská R; Perutka T; Cumová J; Hájek R
    Klin Onkol; 2011; 24(1):35-40. PubMed ID: 21542274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma: Current advances and future directions.
    Ola Landgren C
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101155. PubMed ID: 32139007
    [No Abstract]   [Full Text] [Related]  

  • 17. An update of the management of multiple myeloma: the changing landscape.
    Reece DE
    Hematology Am Soc Hematol Educ Program; 2005; ():353-9. PubMed ID: 16304403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma cell satellitism in plasma cell myeloma.
    Dimov ND; Zynger DL; Peterson LC
    J Clin Pathol; 2006 Sep; 59(9):1003. PubMed ID: 16935984
    [No Abstract]   [Full Text] [Related]  

  • 19. [Phagocytic plasma cells in a patient with multiple myeloma].
    Monsalve CR; Martín CA
    Sangre (Barc); 1991 Feb; 36(1):73-4. PubMed ID: 1853277
    [No Abstract]   [Full Text] [Related]  

  • 20. [Multiple myeloma].
    Krome S
    Dtsch Med Wochenschr; 2012 Mar; 137 Suppl 1():S14-7. PubMed ID: 22438117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.